IP Library Granted Patent US 9,364,460
Granted Patent B2
US 9,364,460 · App. 14/428,232 · Granted Jun 14, 2016

PKC delta inhibitors for use as therapeutics

Inventors: Douglas V. Faller (Weston, MA); Robert M. Williams (Fort Collins, CO)
A61K31/404A61K31/403A61K45/06C07D209/86C07D405/06C07D487/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,364,460
App. No.
14/428,232
Granted
Jun 14, 2016
Kind
B2
Abstract

The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.

Claims (37)

1. A compound of the formula:

wherein:

R 1 is selected from the group consisting of H and a lower alkyl;

R 2 and R 3 are each independently selected from the group consisting of H, OH and OR;

A, B, C, D, W, X, Y, and Z are each independently selected from the group consisting of N and CH;

G is selected from the group consisting of O, NR, S, and CH 2 ,

R is selected from the group consisting of H, a lower alkyl and aryl; and

n is an integer selected from the group consisting of 1, 2, 3, and 4;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 1 is H.

3. The compound of claim 1 . wherein R 2 and R 3 are each independently H or OR, and OR is OH or OCH 3 .

4. The compound of claim 1 , wherein R 2 and R 3 are each H.

5. The compound of claim 1 , wherein A, B, C, D, W, X, Y, and Z are each CH.

6. The compound of claim 1 , wherein G is CH 2 .

7. The compound of claim 1 , wherein n is 1.

8. The compound of claim 1 , wherein n is 2.

9. The compound of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of ammonium, calcium, sodium, and combinations thereof.

10. A compound of the formula;

wherein:

R 1 is H;

R 2 and R 3 are each H;

A, B, C, D, W, X, Y, and Z are each CH; and

G is CH 2 ; and n is an integer selected from the group consisting of 1, 2, 3 and 4; or a pharamaceutically acceptable salt thereof.

11. The compound of claim 10 , wherein n is 1.

12. The compound of claim 10 , wherein n is 2.

13. The compound of claim 10 , in the form of a pharmaceutically acceptable salt.

14. The compound of claim 13 , wherein the pharmaceutically acceptable salt is selected from the group consisting of ammonium, calcium, sodium, and combinations thereof.

15. A compound of the formula:

wherein:

R 1 is H;

R 2 is H;

R 3 is OCH 3 ;

A, B, C, D, W, X, Y, and Z are each CH;

G is CH 2 ; and

n is 1; or a pharmaceutically acceptable salt thereof.

16. The compound of claim 15 , in the form of a pharmaceutically acceptable salt.

17. The compound of claim 16 wherein the pharmaceutically acceptable salt is selected from the group consisting of ammonium, calcium, sodium, and combinations thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 13, 2017
From: BOSTON UNIVERSITY MEDICAL CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042992/0841 →
Continuity (2)
Provisional Application 61703081 · Sep 19, 2012
Related Publication 20150283114A1 · Oct 8, 2015